NCT02462226 (Lymph-Flow) is a NA clinical trial of The-Optimal-Lymph-Flow in Breast Cancer, sponsored by NYU Langone Health.

Who is sponsoring NCT02462226?

NCT02462226 is sponsored by NYU Langone Health.

What drugs are being tested in NCT02462226?

Interventions in NCT02462226: The-Optimal-Lymph-Flow, Arm Precaution.

What condition does NCT02462226 study?

NCT02462226 studies Breast Cancer, Pain, Lymphedema.

Is NCT02462226 still recruiting?

NCT02462226 is currently completed. Last updated 20 April 2017.

Last reviewed 2017-04-20 · How we verify

NCT02462226: Lymph-Flow

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)

Completed NA Last updated 20 April 2017

What this trial tests

NA trial testing The-Optimal-Lymph-Flow in Breast Cancer in 120 participants. Completed in 1 December 2016.

Timeline

1 May 2015

Primary endpoint
1 December 2016

1 December 2016

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	120
Start date	1 May 2015
Primary completion	1 December 2016
Estimated completion	1 December 2016
Sites	1 location across United States

Drugs / interventions tested

The-Optimal-Lymph-Flow
Arm Precaution

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Pain — all drugs for Pain →
Lymphedema — all drugs for Lymphedema →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 21 to 89, female only, with Breast Cancer or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to conduct a randomized clinical trial to evaluate the efficacy of the web-based The-Optimal-Lymph-Flow ™ system for managing chronic pain and symptoms related to lymphedema focusing on primary outcomes of pain reduction, secondary outcomes of symptom relief, limb volume difference by infra-red perometer, body mass index, quality of life related to pain. Recruitment includes 120 patients who will be randomized according to pain/aching/soreness, and tenderness. Participants in the intervention group will be provided the web-based The-Optimal-Lymph-Flow ™ intervention and encourage to access and learn about the program during the 1-4 weeks of the study. Participants in the control group will receive the web-based arm precaution program. All the participants will have monthly online assessment of pain and symptoms at 4 and 8 weeks post-intervention as well as two in-person research visits, that is, prior to intervention and 12 weeks post-intervention.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Web- and Mobile-Based Intervention for Women Treated for Breast Cancer to Manage Chronic Pain and Symptoms Related to Lymphedema: Results of a Randomized Clinical Trial.
Fu MR, Axelrod D, Guth AA, Scagliola J, et al · · 2022 · cited 26× · PMID 35037883 · DOI 10.2196/29485
A Web- and Mobile-Based Intervention for Women Treated for Breast Cancer to Manage Chronic Pain and Symptoms Related to Lymphedema: Randomized Clinical Trial Rationale and Protocol.
Fu MR, Axelrod D, Guth A, Scagliola J, et al · · 2016 · cited 17× · PMID 26795447 · DOI 10.2196/resprot.5104

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02462226 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 20 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02462226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing